APA (7th ed.) Citation

S, R., H, H., I, M., JC, M., M, W., F, M., . . . M, S. (2026). Agonistic GITR treatment enhances antitumor immune responses and suppresses tumor progression in pancreatic ductal adenocarcinoma. Journal of gastroenterology, 61(5), 638. https://doi.org/10.1007/s00535-026-02347-y

Chicago Style (17th ed.) Citation

S, Robatel, et al. "Agonistic GITR Treatment Enhances Antitumor Immune Responses and Suppresses Tumor Progression in Pancreatic Ductal Adenocarcinoma." Journal of Gastroenterology 61, no. 5 (2026): 638. https://doi.org/10.1007/s00535-026-02347-y.

MLA (9th ed.) Citation

S, Robatel, et al. "Agonistic GITR Treatment Enhances Antitumor Immune Responses and Suppresses Tumor Progression in Pancreatic Ductal Adenocarcinoma." Journal of Gastroenterology, vol. 61, no. 5, 2026, p. 638, https://doi.org/10.1007/s00535-026-02347-y.